Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma, Neurotoxicity, Radiation Toxicity
Conditions
Keywords
neurotoxicity, chemotherapeutic agent toxicity, radiation toxicity, cognitive/functional effects, primary central nervous system non-Hodgkin lymphoma
Brief summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vincristine sulfate, procarbazine hydrochloride, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill cancer cells. It is not yet know whether rituximab and combination chemotherapy are more effective when given with or without radiation therapy in treating patients with primary central nervous system lymphoma. PURPOSE: This randomized phase II trial studies how well giving rituximab and combination chemotherapy with or without radiation therapy works in treating patients with primary central nervous system lymphoma.
Detailed description
OBJECTIVES: Primary * To determine median progression-free survival (PFS) in both arms on an intent-to-treat basis. Secondary * To determine overall survival (OS) defined as the interval from randomization to death due to any cause. * To determine treatment-related neurotoxicity rates and disease-related cognitive deterioration in each arm, through the following methods: prospective formal neuropsychological evaluation, utilizing competing-risk methodology to account for death as a competing risk to neurotoxicity or cognitive deterioration from relapsed tumor burden/salvage treatment and incidence of clinically defined neurotoxicity as per investigator's assessment. * To determine if there exists differences between the two treatment arms in terms of health-related quality-of-life and symptoms over time. * To determine response (partial response (PR) and complete response (CR)) rate after methotrexate-based chemotherapy and after consolidation whole-brain radiotherapy (WBRT). * To determine chemotherapy-related toxicity, measured by Common Toxicity Criteria for Adverse Effects (CTCAE), v.4.0. OUTLINE: This is a multicenter study. Patients are stratified according to Memorial Sloan-Kettering Cancer Center recursive-partitioning analysis (RPA) classification for primary central nervous system lymphoma on age and Karnofsky performance status (KPS) (Class 1: age ≤ 50 years vs Class 2: age \> 50 years and KPS ≥ 70% vs Class 3: age \> 50 years and KPS \< 70%). Patients are randomized to 1 of 2 treatment arms.
Interventions
BIOLOGICALRituximab
One 28-day cycle = 500 mg/m\^2 intravenously on day 1 and day 5.
DRUGCytarabine
One 28-day cycle = 3 g/m\^2 intravenously on day 1 and day 2.
DRUGMethotrexate
One 28-day cycle = 3.5 g/m\^2 intravenously (standard hydration/leucovorin support) on day 2.
DRUGProcarbazine
One 28-day cycle = 100 mg/m\^2 orally on days 2-8.
DRUGVincristine
One 28-day cycle = 1.4 mg/m\^2 intravenously, dose capped at 2.4mg, on day 2 and day 16.
RADIATIONlow-dose whole-brain radiation therapy
Total dose of 2340 cGy administered as 13 daily fractions of 180 cGy over 3 weeks. Participants with progressive disease on magnetic resonance imaging (MRI) do not receive WBRT.
Sponsors
National Cancer Institute (NCI)
NRG Oncology
Radiation Therapy Oncology Group
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. B-cell non-Hodgkin's lymphoma(NHL) involving the brain, as demonstrated by contrast-enhanced Magnetic resonance imaging (MRI) and histologic confirmation by one of the following within 6 weeks prior to registration: * A positive cerebral spinal fluid (CSF) cytology for lymphoma or a monoclonal lymphocyte population as defined by cell surface markers * A biopsy of the vitreous or uvea demonstrating non-Hodgkin's lymphoma * Brain biopsy Note: Patients in whom the type of lymphoma could not be determined or is unknown (eg, not enough tissue for further analysis) are assumed to have a B cell lymphoma and are eligible. 2. The patient must agree to submit tissue (i.e., the original H/E stained slides and immunohistochemistry studies) for central pathology review post-registration. 3. No evidence of systemic non-Hodgkin lymphoma as demonstrated by a computed tomography (CT) scan of the chest, abdomen and pelvis within 6 weeks prior to registration (Note: Bone marrow biopsy is not required for registration but must be obtained prior to start of treatment.) 4. Age ≥ 18 5. History and physical examination within 6 weeks of registration 6. Karnofsky performance status (KPS) equal to 50 or higher, with the following exception • Patients with KPS 30 to 50 are eligible if the reason for the poor performance status is neurologic deficit from primary central nervous system (CNS) lymphoma. (Patients with KPS 30 to 50 due to reasons other than primary CNS lymphoma are ineligible. Patients with KPS under 30 for any reason are ineligible) 7. Patient must have documentation of negative HIV-1 testing within 6 weeks prior to study registration (Separate counseling and consent as per institutional guidelines) 8. Complete blood count (CBC)/differential obtained within 2 weeks prior to study registration, with adequate bone marrow function defined as follows: * Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3; * Platelets ≥ 100,000 cells/mm3; * Hemoglobin (Hgb) ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.); 9. Adequate liver function within 2 weeks prior to study registration, defined as follows: * Bilirubin \< 2.0 mg/dl * Aspartate aminotransferase (AST) \<2.5 times upper limit of normal 10. Adequate renal function within 2 weeks prior to study registration, defined as follows * Serum creatinine \< 1.5 mg/dl * Calculated creatinine clearance (CrCl) \> 50cc/min/1.73m2, using the Cockcroft-Gault equation, as follows: Male: CrCl (ml/min) = (140-age) X (Actual weight in kg) / 72 x serum Creatinine (mg/dl). Female: CrCl (ml/min) = (140-age) X (Actual weight in kg) X 0.85 / 72 x serum Creatinine (mg/dl). Note: A measured CrCl from a 24 hour urine collection may also be used. 11. Women of childbearing potential and male participants must agree to practice adequate contraception during therapy 12. Patient must provide study-specific informed consent prior to study registration 13. Patient must be able to swallow pills.
Exclusion criteria
1. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) 2. Prior treatment with chemotherapy or radiotherapy for lymphoma or chronic lymphocytic leukemia; note that prior chemotherapy for a different cancer is allowable; see section 1 3. Prior cranial irradiation 4. Severe, active co-morbidity, defined as follows: * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months; * Transmural myocardial infarction within the last 6 months; * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol. * Known pre-existing immunodeficiency as seen in organ transplant recipient. 5. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic. 6. Prior allergic reaction to any of the study drugs involved in this protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | From randomization to last follow-up. Maximum follow-up at time of analysis was 7.3 years. | Progression is defined as any of the following: more than 25% increase in the contrast-enhancing lesion seen on magnetic resonance imaging (MRI) compared with baseline or best response; new site of disease (central nervous system or systemic); recurrent or new ocular disease; recurrent or positive cerebrospinal fluid (CSF) cytology. Progression-free survival time is defined as time from randomization to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | From randomization to last follow-up. Maximum follow-up at time of analysis was 7.3 years. | Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. |
| Percentage of Participants Experiencing Partial Response or Complete Response | After 4th cycle of chemotherapy, approximately 4 months after randomization. | Response was evaluated using the international criteria proposed by the International Primary Central Nervous System Lymphoma (PCNSL) Study Group criteria. Complete Response was defined as no contrast brain enhancement on magnetic resonance imaging (MRI), no corticosteroid use for at least 2 weeks, a normal eye exam, and negative CSF cytology. Partial response was defined as at least 50% decrease in enhancing tumor on MRI compared with baseline imaging, no or minor retinal pigment epithelium (RPE) abnormality, and negative CSF cytology. |
| Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | EORTC QLQ-C30 was administered at baseline, after cycle 4 of treatment (4 months), then every six months after end of treatment (7 months) for five years. | Global Health Status is calculated from two questions on the EORTC QLQ-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Data through five years after end of protocol treatment is included in the analysis, while summary data is provided only through three years due to very few participants after that timepoint. |
| Percentage of Participants With Neurocognitive Failure | Neurocognitive function tests were administered at baseline, after cycle 4 of treatment (4 months), then every six months after end of treatment (7 months) for five years. Two-year rates are provided here. | Neurocognitive failure is defined as cognitive failure on two or more of the following tests: Hopkins Verbal Learning Test - Revised (HVLT-R) Free Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Trail Making Test Part A, Trail Making Test Part B, and Controlled Oral Word Association. Cognitive failure for each test is defined as a change from baseline in raw score (post baseline score - baseline score) at or exceeding the minimally important difference reported in the literature \[determined by the reliable change index (RCI) method\] of -5, -3, -2,12, 26, and -12, respectively, indicating a worsening of neurocognitive function. Time to neurocognitive failure is defined as time from randomization to date of first failure, last known follow-up (censored), or death without failure (competing risk). Failure rates are estimated using the cumulative incidence method and the distributions of failure times are compared between the arms. Two-year estimates are provided here. |
| Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | At the end of each chemotherapy 28-day cycle, then every 2 months for two years starting 4 weeks after treatment, then every 6 months for 3 years, then yearly. Maximum follow-up at time of analysis was 7.3 years. | Common Terminology Criteria for Adverse Events (version 4.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. Adverse events reported as definitely, probably, or possibly related to protocol treatment are considered to be related to treatment. |
Countries
Israel, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Chemotherapy Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 3-5 weeks later by two 28-day cycles of cytarabine. | 44 |
| Chemotherapy + Low-Dose WBRT Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 2-5 weeks later by 3 weeks of low-dose whole-brain radiotherapy (WBRT), followed 3-5 weeks later by two 28-day cycles of cytarabine. | 43 |
| Total | 87 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Protocol Violation | 3 | 1 |
Baseline characteristics
| Characteristic | Chemotherapy | Total | Chemotherapy + Low-Dose WBRT |
|---|---|---|---|
| Age, Customized | 59.5 years | 63 years | 66 years |
| Cerebrospinal fluid (CSF) Involvement | 5 Participants | 11 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 2 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 38 Participants | 75 Participants | 37 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 5 Participants | 10 Participants | 5 Participants |
| Karnofsky Performance Status (KPS) 30-50 | 5 Participants | 11 Participants | 6 Participants |
| Karnofsky Performance Status (KPS) 60-80 | 23 Participants | 45 Participants | 22 Participants |
| Karnofsky Performance Status (KPS) 90-100 | 16 Participants | 31 Participants | 15 Participants |
| Memorial Sloan-Kettering Cancer Center (MSKCC) Recursive Partitioning analysis (RPA) Class Class 1 | 7 Participants | 13 Participants | 6 Participants |
| Memorial Sloan-Kettering Cancer Center (MSKCC) Recursive Partitioning analysis (RPA) Class Class 2 | 26 Participants | 51 Participants | 25 Participants |
| Memorial Sloan-Kettering Cancer Center (MSKCC) Recursive Partitioning analysis (RPA) Class Class 3 | 11 Participants | 23 Participants | 12 Participants |
| Neurologic Symptoms Minor | 15 Participants | 31 Participants | 16 Participants |
| Neurologic Symptoms Moderate | 18 Participants | 32 Participants | 14 Participants |
| Neurologic Symptoms None | 8 Participants | 15 Participants | 7 Participants |
| Neurologic Symptoms Severe | 3 Participants | 9 Participants | 6 Participants |
| Ocular Involvement | 3 Participants | 3 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 6 Participants | 8 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants | 9 Participants | 4 Participants |
| Race (NIH/OMB) White | 33 Participants | 70 Participants | 37 Participants |
| Sex: Female, Male Female | 22 Participants | 42 Participants | 20 Participants |
| Sex: Female, Male Male | 22 Participants | 45 Participants | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 3 / 44 | 1 / 43 |
| other Total, other adverse events | 42 / 43 | 43 / 43 |
| serious Total, serious adverse events | 22 / 43 | 21 / 43 |
Outcome results
Primary
Progression-free Survival
Progression is defined as any of the following: more than 25% increase in the contrast-enhancing lesion seen on magnetic resonance imaging (MRI) compared with baseline or best response; new site of disease (central nervous system or systemic); recurrent or new ocular disease; recurrent or positive cerebrospinal fluid (CSF) cytology. Progression-free survival time is defined as time from randomization to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method.
Time frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 7.3 years.
Population: Eligible participants
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Chemotherapy | Progression-free Survival | 2.1 years |
| Chemotherapy + Low-Dose WBRT | Progression-free Survival | NA years |
Comparison: Sample size of 89 provided 80% power to detect a hazard ratio of 0.63 at a one-sided alpha level of 0.15.p-value: 0.01595% CI: [0.27, 0.95]Log Rank
Secondary
Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment
Common Terminology Criteria for Adverse Events (version 4.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. Adverse events reported as definitely, probably, or possibly related to protocol treatment are considered to be related to treatment.
Time frame: At the end of each chemotherapy 28-day cycle, then every 2 months for two years starting 4 weeks after treatment, then every 6 months for 3 years, then yearly. Maximum follow-up at time of analysis was 7.3 years.
Population: Eligible participants who started protocol treatment
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Chemotherapy | Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | None | 2 Participants |
| Chemotherapy | Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | Grade 1 | 3 Participants |
| Chemotherapy | Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | Grade 2 | 4 Participants |
| Chemotherapy | Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | Grade 3 | 20 Participants |
| Chemotherapy | Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | Grade 4 | 14 Participants |
| Chemotherapy | Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | Grade 5 | 0 Participants |
| Chemotherapy + Low-Dose WBRT | Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | Grade 4 | 13 Participants |
| Chemotherapy + Low-Dose WBRT | Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | None | 3 Participants |
| Chemotherapy + Low-Dose WBRT | Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | Grade 3 | 15 Participants |
| Chemotherapy + Low-Dose WBRT | Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | Grade 1 | 6 Participants |
| Chemotherapy + Low-Dose WBRT | Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | Grade 5 | 1 Participants |
| Chemotherapy + Low-Dose WBRT | Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment | Grade 2 | 5 Participants |
Secondary
Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Global Health Status is calculated from two questions on the EORTC QLQ-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Data through five years after end of protocol treatment is included in the analysis, while summary data is provided only through three years due to very few participants after that timepoint.
Time frame: EORTC QLQ-C30 was administered at baseline, after cycle 4 of treatment (4 months), then every six months after end of treatment (7 months) for five years.
Population: Eligible, consented to quality of life study component, and has GHS score for at least one timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Chemotherapy | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | Baseline | 62.78 score on a scale | Standard Deviation 23.54 |
| Chemotherapy | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 30 Months Post-Treatment | 77.08 score on a scale | Standard Deviation 24.13 |
| Chemotherapy | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 6 Months Post-Treatment | 74.54 score on a scale | Standard Deviation 20.7 |
| Chemotherapy | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 36 Months Post-Treatment | 75.00 score on a scale | Standard Deviation 27.78 |
| Chemotherapy | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 42 Months Post-Treatment | 75.00 score on a scale | Standard Deviation 21.52 |
| Chemotherapy | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 12 Months Post-Treatment | 78.47 score on a scale | Standard Deviation 22.88 |
| Chemotherapy | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 48 Months Post-Treatment | 79.76 score on a scale | Standard Deviation 21.97 |
| Chemotherapy | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | End of cycle 4 | 67.67 score on a scale | Standard Deviation 23.97 |
| Chemotherapy | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 54 Months Post-Treatment | 70.24 score on a scale | Standard Deviation 16.67 |
| Chemotherapy | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 18 Months Post-Treatment | 76.79 score on a scale | Standard Deviation 20.46 |
| Chemotherapy | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 60 Months Post-Treatment | 80.56 score on a scale | Standard Deviation 17.35 |
| Chemotherapy | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 24 Months Post-Treatment | 70.83 score on a scale | Standard Deviation 25 |
| Chemotherapy + Low-Dose WBRT | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 60 Months Post-Treatment | 83.33 score on a scale | — |
| Chemotherapy + Low-Dose WBRT | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | Baseline | 54.90 score on a scale | Standard Deviation 26.91 |
| Chemotherapy + Low-Dose WBRT | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | End of cycle 4 | 64.58 score on a scale | Standard Deviation 20.49 |
| Chemotherapy + Low-Dose WBRT | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 6 Months Post-Treatment | 75.35 score on a scale | Standard Deviation 20.48 |
| Chemotherapy + Low-Dose WBRT | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 12 Months Post-Treatment | 78.99 score on a scale | Standard Deviation 24.73 |
| Chemotherapy + Low-Dose WBRT | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 24 Months Post-Treatment | 83.33 score on a scale | Standard Deviation 21.43 |
| Chemotherapy + Low-Dose WBRT | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 30 Months Post-Treatment | 79.63 score on a scale | Standard Deviation 17.9 |
| Chemotherapy + Low-Dose WBRT | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 36 Months Post-Treatment | 85.00 score on a scale | Standard Deviation 13.8 |
| Chemotherapy + Low-Dose WBRT | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 42 Months Post-Treatment | 77.56 score on a scale | Standard Deviation 19.95 |
| Chemotherapy + Low-Dose WBRT | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 48 Months Post-Treatment | 84.38 score on a scale | Standard Deviation 19.64 |
| Chemotherapy + Low-Dose WBRT | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 54 Months Post-Treatment | 91.67 score on a scale | Standard Deviation 10.21 |
| Chemotherapy + Low-Dose WBRT | Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 18 Months Post-Treatment | 76.67 score on a scale | Standard Deviation 24.27 |
Comparison: A mixed effects model of EORTC QLQ-C30 GHS was run with independent variables treatment arm, time, baseline Memorial Sloan-Kettering Cancer Center (MSKCC) recursive partitioning analysis (RPA) class, and baseline neurologic symptoms (none/minor vs. moderate/severe), including the interaction of treatment and time, representing difference in the longitudinal trajectory of the scores between the treatment arms. Prospectively, the interaction effect was of most interest and is reported here,p-value: 0.005Mixed Models Analysis
Secondary
Overall Survival
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method.
Time frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 7.3 years.
Population: Eligible participants
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Chemotherapy | Overall Survival | NA years |
| Chemotherapy + Low-Dose WBRT | Overall Survival | NA years |
p-value: 0.4895% CI: [0.38, 1.58]Log Rank
Secondary
Percentage of Participants Experiencing Partial Response or Complete Response
Response was evaluated using the international criteria proposed by the International Primary Central Nervous System Lymphoma (PCNSL) Study Group criteria. Complete Response was defined as no contrast brain enhancement on magnetic resonance imaging (MRI), no corticosteroid use for at least 2 weeks, a normal eye exam, and negative CSF cytology. Partial response was defined as at least 50% decrease in enhancing tumor on MRI compared with baseline imaging, no or minor retinal pigment epithelium (RPE) abnormality, and negative CSF cytology.
Time frame: After 4th cycle of chemotherapy, approximately 4 months after randomization.
Population: Eligible participants with Cycle 4 disease assessment data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Chemotherapy | Percentage of Participants Experiencing Partial Response or Complete Response | 83.3 percentage of participants |
| Chemotherapy + Low-Dose WBRT | Percentage of Participants Experiencing Partial Response or Complete Response | 80.6 percentage of participants |
Secondary
Percentage of Participants With Neurocognitive Failure
Neurocognitive failure is defined as cognitive failure on two or more of the following tests: Hopkins Verbal Learning Test - Revised (HVLT-R) Free Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Trail Making Test Part A, Trail Making Test Part B, and Controlled Oral Word Association. Cognitive failure for each test is defined as a change from baseline in raw score (post baseline score - baseline score) at or exceeding the minimally important difference reported in the literature \[determined by the reliable change index (RCI) method\] of -5, -3, -2,12, 26, and -12, respectively, indicating a worsening of neurocognitive function. Time to neurocognitive failure is defined as time from randomization to date of first failure, last known follow-up (censored), or death without failure (competing risk). Failure rates are estimated using the cumulative incidence method and the distributions of failure times are compared between the arms. Two-year estimates are provided here.
Time frame: Neurocognitive function tests were administered at baseline, after cycle 4 of treatment (4 months), then every six months after end of treatment (7 months) for five years. Two-year rates are provided here.
Population: Eligible, consented to neurocognitive function study component and has at least two completed neurocognitive tests at baseline and at least one post baseline visit.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Chemotherapy | Percentage of Participants With Neurocognitive Failure | 31.6 percentage of participants |
| Chemotherapy + Low-Dose WBRT | Percentage of Participants With Neurocognitive Failure | 17.9 percentage of participants |
p-value: 0.1895% CI: [0.21, 1.31]Gray's test